ATRA Stock Recent News
ATRA LATEST HEADLINES
Penny stocks to buy or avoid? 3 for your watch list right now.
The small-cap Russell 2000 gained over 10% in July, compared to a jump of 9.1% for the S&P 500.
Atara has two possible regulatory approvals for tab-cel for PTLD; European approval expected Q4 of 2022 and BLA filing for U.S. territory to be updated in next quarter earnings call. Two data readouts of ATA188 for treatment of patients with progressive multiple sclerosis; Phase 1 MRI Data/OLE data Q4 2022 and phase 2 EMBOLD study data expected October 2023.
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 65.93% and 483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
After Plunging 65.7% in 4 Weeks, Here's Why the Trend Might Reverse for Atara Biotherapeutics (ATRA)
Atara Biotherapeutics (ATRA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Investors were hoping for more from the company's latest clinical update.
Atara Biotherapeutics Inc (NASDAQ: ATRA) issued its anticipated interim analysis communication for its ATA188 Phase 2 progressive multiple sclerosis trial. Shares slumped over 50%.
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Atara Biotherapeutics Inc (NASDAQ: ATRA) completed the planned Interim Analysis of the ATA188 Phase 2 study (EMBOLD) in progressive multiple sclerosis patients. The analysis' primary focus was on expanded disability status scale (EDSS) improvement at six months and overall.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will disclose its completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis via press release after market close on Tuesday, July 12, 2022. Following the release, the Company will hos